These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23122783)

  • 21. [A case of HER2-positive breast cancer receiving lapatinib+capecitabine chemotherapy with ventriculoperitoneal shunting for hydrocephalus associated with brain metastases].
    Makino T; Kawamura H; Yokoyama E; Kato Y; Nishina M
    Gan To Kagaku Ryoho; 2012 Jul; 39(7):1115-7. PubMed ID: 22790050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
    Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
    Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
    Lin NU; Diéras V; Paul D; Lossignol D; Christodoulou C; Stemmler HJ; Roché H; Liu MC; Greil R; Ciruelos E; Loibl S; Gori S; Wardley A; Yardley D; Brufsky A; Blum JL; Rubin SD; Dharan B; Steplewski K; Zembryki D; Oliva C; Roychowdhury D; Paoletti P; Winer EP
    Clin Cancer Res; 2009 Feb; 15(4):1452-9. PubMed ID: 19228746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel targeted therapies in inflammatory breast cancer.
    Cristofanilli M
    Cancer; 2010 Jun; 116(11 Suppl):2837-9. PubMed ID: 20503416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current possibilities of targeted therapy in the treatment of breast cancer with overexpression of HER-2/neu and metastatic lesions in the brain].
    Naskhletashvili DR; Gorbunova VA; Moskvina EA
    Vopr Onkol; 2013; 59(3):347-51. PubMed ID: 23909036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.
    Zhou X; Cella D; Cameron D; Amonkar MM; Segreti A; Stein S; Walker M; Geyer CE
    Breast Cancer Res Treat; 2009 Oct; 117(3):577-89. PubMed ID: 19153829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capecitabine dosing is not yet optimized for breast cancer.
    Hudis C; Traina T; Norton L
    Ann Oncol; 2010 Nov; 21(11):2291; author reply 2291-2. PubMed ID: 20501505
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A Case of Effective Whole-Brain Irradiation and Lapatinib/Capecitabine Combination Therapy for HER2-Positive Breast Cancer with Multiple Brain Metastases].
    Shibasaki M; Tanabe A; Toda T; Sakata H; Ijichi M; Kusaka K; Bandai Y
    Gan To Kagaku Ryoho; 2015 Jun; 42(6):755-7. PubMed ID: 26199252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.
    Niravath P; Tham YL; Wang T; Rodriguez A; Foreman C; Hilsenbeck SG; Elledge R; Rimawi M
    Oncologist; 2015 Jan; 20(1):13. PubMed ID: 25378456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].
    Bachelot T; Le Rhun E; Labidi-Gally I; Heudel P; Gilabert M; Bonneterre J; Pierga JY; Gonçalves A
    Bull Cancer; 2013 Jan; 100(1):7-14. PubMed ID: 23305997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Length of chemotherapy and use of bevacizumab for breast cancer.
    Brufsky A
    Lancet Oncol; 2014 Nov; 15(12):1285-7. PubMed ID: 25439683
    [No Abstract]   [Full Text] [Related]  

  • 33. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
    Cetin B; Benekli M; Turker I; Koral L; Ulas A; Dane F; Oksuzoglu B; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
    J Chemother; 2014 Oct; 26(5):300-5. PubMed ID: 24112786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
    Kefeli U; Bilici A; Ustaalioglu BB; Kefeli AU; Yildirim ME; Seker M; Gumus M
    Arch Gynecol Obstet; 2011 Feb; 283(2):405-7. PubMed ID: 20495812
    [No Abstract]   [Full Text] [Related]  

  • 35. Dramatic regression of multiple brain metastases from breast cancer with Capecitabine: another arrow at the bow?
    Fabi A; Vidiri A; Ferretti G; Felici A; Papaldo P; Carlini P; Mirri A; Nuzzo C; Cognetti F
    Cancer Invest; 2006; 24(4):466-8. PubMed ID: 16777702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V
    J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy.
    Shimada K; Ishikawa T; Yoneyama S; Kita K; Narui K; Sugae S; Shimizu D; Tanabe M; Sasaki T; Chishima T; Ichikawa Y; Endo I
    Anticancer Res; 2013 Nov; 33(11):5119-21. PubMed ID: 24222158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
    Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
    Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lapatinib: new drug. For some women with metastatic breast cancer.
    Prescrire Int; 2009 Feb; 18(99):9. PubMed ID: 19382400
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
    Rivera E; Meyers C; Groves M; Valero V; Francis D; Arun B; Broglio K; Yin G; Hortobagyi GN; Buchholz T
    Cancer; 2006 Sep; 107(6):1348-54. PubMed ID: 16909414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.